CoChat

ALDH2 contributes to melatonin-induced protection against APP/PS1 mutation-prompted cardiac anomalies through cGAS-STING-TBK1-mediated regulation of mitophagy

Open access

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

Ample clinical evidence suggests a high incidence of cardiovascular events in Alzheimer’s disease (AD), although neither precise etiology nor effective treatment is available. This study was designed to evaluate cardiac function in AD patients and APP/PS1 mutant mice, along with circulating levels of melatonin, mitochondrial aldehyde dehydrogenase (ALDH2) and autophagy. AD patients and APP/PS1 mice displayed cognitive and myocardial deficits, low levels of circulating melatonin, ALDH2 activity, and autophagy, ultrastructural, geometric (cardiac atrophy and interstitial fibrosis) and functional (reduced fractional shortening and cardiomyocyte contraction) anomalies, mitochondrial injury, cytosolic mtDNA buildup, apoptosis, and suppressed autophagy and mitophagy. APP/PS1 mutation downregulated cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) levels and TBK1 phosphorylation, while promoting Aβ accumulation. Treatment with melatonin overtly ameliorated unfavorable APP/PS1-induced changes in cardiac geometry and function, apoptosis, mitochondrial integrity, cytosolic mtDNA accumulation (using both immunocytochemistry and qPCR), mitophagy, and cGAS-STING-TBK1 signaling, although these benefits were absent in APP/PS1/ALDH2 −/− mice. In vitro evidence indicated that melatonin attenuated APP/PS1-induced suppression of mitophagy and cardiomyocyte function, and the effect was negated by the nonselective melatonin receptor blocker luzindole, inhibitors or RNA interference of cGAS, STING, TBK1, and autophagy. Our data collectively established a correlation among cardiac dysfunction, low levels of melatonin, ALDH2 activity, and autophagy in AD patients, with compelling support in APP/PS1 mice, in which melatonin rescued myopathic changes by promoting cGAS-STING-TBK1 signaling and mitophagy via an ALDH2-dependent mechanism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-0171-5

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Heart function and melatonin levels in Alzheimer’s disease patients and age-matched controls. a Heart rate; b end systolic volume; c end diastolic volume; d ejection fraction (%); e stroke volume; f septum wall thickness; g dP/dT; h LVDP (left ventricular diastolic pressure); and i circulating melatonin concentration. The data are shown as the mean ± SEM, n = 26 individuals per group, and all p-values shown were calculated using Student’s t-tests
Fig. 1 Heart function and melatonin levels in Alzheimer’s disease patients and age-matched controls. a Heart rate; b end systolic volume; c end diastolic volume; d ejection fraction (%); e stroke volume; f septum wall thickness; g dP/dT; h LVDP (left ventricular diastolic pressure); and i circulating melatonin concentration. The data are shown as the mean ± SEM, n = 26 individuals per group, and all p-values shown were calculated using Student’s t-testsCC BY · PubMed Central
Fig. 2 The effect of melatonin (20 mg/kg/day, p.o., 6 weeks) on WT mice and APP/PS1 mice with Alzheimer’s disease. a Escape latency; b time in target quadrant (%); c circulating melatonin level; d body weight; e hHeart weight; f liver weight; g representative image of echocardiography; h left ventricular (LV) wall thickness; i LV end diastolic volume (LVEDD); j LV end systolic volume (LVESD); k fractional shortening; l LV mass/body weight; m heart rate; n representative images of lectin staining showing cardiomyocyte atrophy (×200) and Masson’s trichrome staining depicting fibrosis (×100); o quantitative analysis of cardiomyocyte cross-sectional area; and p quantitative analysis of fibrotic area (Masson’s trichrome-stained area in light blue was normalized to total cardiac area). The data are shown as the mean ± SEM, n = 7–14 mice per group. *p < 0.05 between the indicated groups
Fig. 2 The effect of melatonin (20 mg/kg/day, p.o., 6 weeks) on WT mice and APP/PS1 mice with Alzheimer’s disease. a Escape latency; b time in target quadrant (%); c circulating melatonin level; d body weight; e hHeart weight; f liver weight; g representative image of echocardiography; h left ventricular (LV) wall thickness; i LV end diastolic volume (LVEDD); j LV end systolic volume (LVESD); k fractional shortening; l LV mass/body weight; m heart rate; n representative images of lectin staining showing cardiomyocyte atrophy (×200) and Masson’s trichrome staining depicting fibrosis (×100); o quantitative analysis of cardiomyocyte cross-sectional area; and p quantitative analysis of fibrotic area (Masson’s trichrome-stained area in light blue was normalized to total cardiac area). The data are shown as the mean ± SEM, n = 7–14 mice per group. *p < 0.05 between the indicated groupsCC BY · PubMed Central
Fig. 3 Mitochondrial abnormalities, contractile properties, and intracellular Ca2+ homeostasis in cardiomyocytes in WT, APP/PS1 treated with or without melatonin (20 mg/kg/day, p.o., 6 weeks). a Representative transmission electron microscopy (TEM) images showing ultrastructural findings; b mitochondrial number per cardiac area (×6000); c percentage of mitochondrial area per cardiac area (×6000); d aconitase activity; e representative image of JC-1; f ratio of aggregate/monomeric JC-1; g UCP2 expression; h PGC-1α expression; i peak shortening (normalized to cell length); j maximal velocity of shortening (+dL/dt); k maximal velocity of relengthening (−dL/dt); l time-to–peak shortening (TPS); m time-to-90% relengthening (TR90); n resting fura-2 fluorescence intensity (FFI); o electrically stimulated rise in FFI (ΔFFI); and p single exponential intracellular Ca2+ decay. The data are shown as the mean ± SEM, n = 3 mice per group for b and c, n = 4–7 mice per group for d and f, n = 6–8 mice per group for g and h, n = 80 cells from 5 mice (∼15–20 cells per mouse) per group for i–m, and n = 50 cells from 5 mice (∼10–15 cells per mouse) per group for n–p. *p < 0.05 between the indicated groups
Fig. 3 Mitochondrial abnormalities, contractile properties, and intracellular Ca2+ homeostasis in cardiomyocytes in WT, APP/PS1 treated with or without melatonin (20 mg/kg/day, p.o., 6 weeks). a Representative transmission electron microscopy (TEM) images showing ultrastructural findings; b mitochondrial number per cardiac area (×6000); c percentage of mitochondrial area per cardiac area (×6000); d aconitase activity; e representative image of JC-1; f ratio of aggregate/monomeric JC-1; g UCP2 expression; h PGC-1α expression; i peak shortening (normalized to cell length); j maximal velocity of shortening (+dL/dt); k maximal velocity of relengthening (−dL/dt); l time-to–peak shortening (TPS); m time-to-90% relengthening (TR90); n resting fura-2 fluorescence intensity (FFI); o electrically stimulated rise in FFI (ΔFFI); and p single exponential intracellular Ca2+ decay. The data are shown as the mean ± SEM, n = 3 mice per group for b and c, n = 4–7 mice per group for d and f, n = 6–8 mice per group for g and h, n = 80 cells from 5 mice (∼15–20 cells per mouse) per group for i–m, and n = 50 cells from 5 mice (∼10–15 cells per mouse) per group for n–p. *p < 0.05 between the indicated groupsCC BY · PubMed Central
Fig. 4 ALDH2 activity and the effect of melatonin (20 mg/kg/day, p.o., 6 weeks) on ALDH2−/−-APP/PS1 mice. a Blood ALDH2 activity in Alzheimer’s disease patients and age-matched controls. b PKCε expression in WT and APP/PS1 mice treated with or without melatonin; c cardiomyocyte ALDH2 activity in WT and APP/PS1 mice treated with or without melatonin (100 μΜ) and the PKCε inhibitor εV1–2 (1 µM); d escape latency in WT, ALDH2−/−, ALDH2−/−-APP/PS1 mice, and ALDH2−/−-APP/PS1 mice treated with melatonin; e time in target quadrant; f body weight; g representative image of echocardiography; h left ventricular (LV) wall thickness; i LV end diastolic volume (LVEDD); j LV end systolic volume (LVESD); k fractional shortening; l LV mass/body weight; m heart rate; n representative images of lectin staining showing cardiomyocyte atrophy (×200) and Masson’s trichrome staining depicting fibrosis (×100); o quantitative analysis of cardiomyocyte cross-sectional area; and p quantitative analysis of fibrotic area. The data are shown as the mean ± SEM, n = 5–7 per group for a–c, n = 9–14 mice per group for d–p. *p < 0.05 between the indicated groups
Fig. 4 ALDH2 activity and the effect of melatonin (20 mg/kg/day, p.o., 6 weeks) on ALDH2−/−-APP/PS1 mice. a Blood ALDH2 activity in Alzheimer’s disease patients and age-matched controls. b PKCε expression in WT and APP/PS1 mice treated with or without melatonin; c cardiomyocyte ALDH2 activity in WT and APP/PS1 mice treated with or without melatonin (100 μΜ) and the PKCε inhibitor εV1–2 (1 µM); d escape latency in WT, ALDH2−/−, ALDH2−/−-APP/PS1 mice, and ALDH2−/−-APP/PS1 mice treated with melatonin; e time in target quadrant; f body weight; g representative image of echocardiography; h left ventricular (LV) wall thickness; i LV end diastolic volume (LVEDD); j LV end systolic volume (LVESD); k fractional shortening; l LV mass/body weight; m heart rate; n representative images of lectin staining showing cardiomyocyte atrophy (×200) and Masson’s trichrome staining depicting fibrosis (×100); o quantitative analysis of cardiomyocyte cross-sectional area; and p quantitative analysis of fibrotic area. The data are shown as the mean ± SEM, n = 5–7 per group for a–c, n = 9–14 mice per group for d–p. *p < 0.05 between the indicated groupsCC BY · PubMed Central
Fig. 5 Mitochondrial abnormalities, contractile properties, and intracellular Ca2+ homeostasis of cardiomyocytes in WT, ALDH2−/−, ALDH2−/−-APP/PS1 mice, and ALDH2−/−-APP/PS1 mice treated with melatonin (20 mg/kg/day, p.o., 6 weeks). a Representative transmission electron microscopy (TEM) images showing the ultrastructural findings; b mitochondrial number per cardiac area (×6000); c percentage of mitochondrial area per cardiac area (×6000); d aconitase activity; e representative image of JC-1; f ratio of aggregate/monomeric JC-1; g UCP2 expression; h PGC-1α expression; i peak shortening (normalized to cell length); j maximal velocity of shortening (+dL/dt); k maximal velocity of relengthening (−dL/dt); l Time-to–peak shortening (TPS); m time-to-90% relengthening (TR90); n resting fura-2 fluorescence intensity (FFI); o electrically stimulated rise in FFI (ΔFFI); and p single exponential intracellular Ca2+ decay. The data are shown as the mean ± SEM, n = 3 mice per group for b, c, n = 4–7 mice per group for d–f, n = 6–8 mice per group for g, h, n = 80 cells from 5 mice (∼15–20 cells per mouse) per group for i–m, and n = 50 cells from 5 mice (∼10–15 cells per mouse) per group for n–p. *p < 0.05 between the indicated groups
Fig. 5 Mitochondrial abnormalities, contractile properties, and intracellular Ca2+ homeostasis of cardiomyocytes in WT, ALDH2−/−, ALDH2−/−-APP/PS1 mice, and ALDH2−/−-APP/PS1 mice treated with melatonin (20 mg/kg/day, p.o., 6 weeks). a Representative transmission electron microscopy (TEM) images showing the ultrastructural findings; b mitochondrial number per cardiac area (×6000); c percentage of mitochondrial area per cardiac area (×6000); d aconitase activity; e representative image of JC-1; f ratio of aggregate/monomeric JC-1; g UCP2 expression; h PGC-1α expression; i peak shortening (normalized to cell length); j maximal velocity of shortening (+dL/dt); k maximal velocity of relengthening (−dL/dt); l Time-to–peak shortening (TPS); m time-to-90% relengthening (TR90); n resting fura-2 fluorescence intensity (FFI); o electrically stimulated rise in FFI (ΔFFI); and p single exponential intracellular Ca2+ decay. The data are shown as the mean ± SEM, n = 3 mice per group for b, c, n = 4–7 mice per group for d–f, n = 6–8 mice per group for g, h, n = 80 cells from 5 mice (∼15–20 cells per mouse) per group for i–m, and n = 50 cells from 5 mice (∼10–15 cells per mouse) per group for n–p. *p < 0.05 between the indicated groupsCC BY · PubMed Central
Fig. 6 Effect of melatonin on apoptosis levels in WT, APP/PS1, ALDH2-knockout (ALDH2−/−), and ALDH2−/−-APP/PS1 mice. a Representative image of TUNEL; b TUNEL-positive cardiomyocytes per 100 cells; c representative gel depicting ALDH2, the apoptosis markers Bax, Bcl-2, Caspase 3, Caspase 9, and cytochrome C and GAPDH (loading control) levels using specific antibodies; d ALDH2 expression; e Bax level; f Bcl-2 level; g Caspase 3 level; h Caspase 9 level; and i cytochrome C level. The data are shown as the mean ± SEM, n = 5–8 mice per group. *p < 0.05 between the indicated groups
Fig. 6 Effect of melatonin on apoptosis levels in WT, APP/PS1, ALDH2-knockout (ALDH2−/−), and ALDH2−/−-APP/PS1 mice. a Representative image of TUNEL; b TUNEL-positive cardiomyocytes per 100 cells; c representative gel depicting ALDH2, the apoptosis markers Bax, Bcl-2, Caspase 3, Caspase 9, and cytochrome C and GAPDH (loading control) levels using specific antibodies; d ALDH2 expression; e Bax level; f Bcl-2 level; g Caspase 3 level; h Caspase 9 level; and i cytochrome C level. The data are shown as the mean ± SEM, n = 5–8 mice per group. *p < 0.05 between the indicated groupsCC BY · PubMed Central
Fig. 7 Circulating Beclin1 levels in Alzheimer’s disease patients (n = 28) and age-matched controls (n = 25), and the effect of melatonin (20 mg/kg/day, p.o., 6 weeks) on autophagy and mitophagy levels in WT, APP/PS1, ALDH2-knockout (ALDH2−/−), and ALDH2−/−-APP/PS1 mice. a Circulating Beclin1 level; b LC3BII to I ratio; c Beclin1 level; d Atg5 level; e p62 level; f Parkin level; g Pink1 level; h FundC1 level; i Bnip3 level; j Aβ level; k cGAS level; l STING level; m TBK1 level; n phosphor-TBK1 level; o qPCR assessment of in vivo cytosolic mtDNA levels from adult mouse hearts; and p representative immunocytochemistry images of cytosolic DNA accumulation in neonatal mouse cardiomyocytes from WT, APP/PS1, ALDH2 knockout (ALDH2−/−), and ALDH2−/−-APP/PS1 neonates treated with or without melatonin (Mel, 100 μΜ) for 4 h prior to assessing mtDNA using a dsDNA antibody and MitoTracker. mtDNA (dsDNA colocalized with MitoTracker, yellow dots), nuclear DNA (dsDNA in the nucleus colocalized with DAPI), and cytosolic DNA (dsDNA not colocalized with mitochondria or the nucleus, green dots) are presented. APP/PS1 mutation promotes buildup of cytosolic dsDNA, which was mitigated by melatonin treatment, whereas ALDH2 ablation abrogated the beneficial effect of melatonin, n = 4 biological repeats for p. The data are shown as the mean ± SEM, n = 5–9 mice per group. *p < 0.05 between the indicated groups
Fig. 7 Circulating Beclin1 levels in Alzheimer’s disease patients (n = 28) and age-matched controls (n = 25), and the effect of melatonin (20 mg/kg/day, p.o., 6 weeks) on autophagy and mitophagy levels in WT, APP/PS1, ALDH2-knockout (ALDH2−/−), and ALDH2−/−-APP/PS1 mice. a Circulating Beclin1 level; b LC3BII to I ratio; c Beclin1 level; d Atg5 level; e p62 level; f Parkin level; g Pink1 level; h FundC1 level; i Bnip3 level; j Aβ level; k cGAS level; l STING level; m TBK1 level; n phosphor-TBK1 level; o qPCR assessment of in vivo cytosolic mtDNA levels from adult mouse hearts; and p representative immunocytochemistry images of cytosolic DNA accumulation in neonatal mouse cardiomyocytes from WT, APP/PS1, ALDH2 knockout (ALDH2−/−), and ALDH2−/−-APP/PS1 neonates treated with or without melatonin (Mel, 100 μΜ) for 4 h prior to assessing mtDNA using a dsDNA antibody and MitoTracker. mtDNA (dsDNA colocalized with MitoTracker, yellow dots), nuclear DNA (dsDNA in the nucleus colocalized with DAPI), and cytosolic DNA (dsDNA not colocalized with mitochondria or the nucleus, green dots) are presented. APP/PS1 mutation promotes buildup of cytosolic dsDNA, which was mitigated by melatonin treatment, whereas ALDH2 ablation abrogated the beneficial effect of melatonin, n = 4 biological repeats for p. The data are shown as the mean ± SEM, n = 5–9 mice per group. *p < 0.05 between the indicated groupsCC BY · PubMed Central
Fig. 8 Melatonin restores mitophagy and contractile function through the ALDH2-cGAS-STING-TBK1 signaling pathway. a Representative images of GFP-LC3, MitoTracker, DAPI staining, and merged images in WT and APP/PS1 neonatal cardiomyocytes treated with or without melatonin (Mel, 100 μΜ), PF-06928215 (cGAS inhibitor, 10 μM), Astin (STING inhibitor, 10 μM), c-diAM(PS)2 (STING activator, 2.7 μM), and BX795 (TBK activator, 1 μM). b Quantitative analysis of GFP-LC3 and MitoTracker colocalized puncta per cell; c peak shortening (normalized to cell length); d maximal velocity of shortening (+dL/dt); e maximal velocity of relengthening (−dL/dt); and f time-to-90% relengthening (TR90). The data are shown as the mean ± SEM, n = 5 replicates per group for b, n = 27–31 cells from 3 mice (∼10 cells per mouse) per group for c–f. *p < 0.05 between the indicated groups
Fig. 8 Melatonin restores mitophagy and contractile function through the ALDH2-cGAS-STING-TBK1 signaling pathway. a Representative images of GFP-LC3, MitoTracker, DAPI staining, and merged images in WT and APP/PS1 neonatal cardiomyocytes treated with or without melatonin (Mel, 100 μΜ), PF-06928215 (cGAS inhibitor, 10 μM), Astin (STING inhibitor, 10 μM), c-diAM(PS)2 (STING activator, 2.7 μM), and BX795 (TBK activator, 1 μM). b Quantitative analysis of GFP-LC3 and MitoTracker colocalized puncta per cell; c peak shortening (normalized to cell length); d maximal velocity of shortening (+dL/dt); e maximal velocity of relengthening (−dL/dt); and f time-to-90% relengthening (TR90). The data are shown as the mean ± SEM, n = 5 replicates per group for b, n = 27–31 cells from 3 mice (∼10 cells per mouse) per group for c–f. *p < 0.05 between the indicated groupsCC BY · PubMed Central
Fig. 9 Melatonin protects against AD-associated heart dysfunction through ALDH2 and cGAS-STING-TBK1 signaling. AD is associated with decreased melatonin levels, which leads to suppressed ALDH2 activity. Impaired activity of the mitochondrial protein ALDH2 results in damage to mitochondrial integrity, causing mtDNA to be released into the cytosol. A large amount of mtDNA depletes cGAS-STING-TBK1 signaling, leading to suppressed levels of autophagy and mitophagy. These responses further impair clearance of Aβ and mitochondria, ultimately resulting in heart dysfunction. Melatonin supplementation protects heart function in AD by boosting ALDH2 activity through PKCε, thus restoring mitochondrial integrity, cGAS-STING-TBK1 signaling, and autophagy and mitophagy levels
Fig. 9 Melatonin protects against AD-associated heart dysfunction through ALDH2 and cGAS-STING-TBK1 signaling. AD is associated with decreased melatonin levels, which leads to suppressed ALDH2 activity. Impaired activity of the mitochondrial protein ALDH2 results in damage to mitochondrial integrity, causing mtDNA to be released into the cytosol. A large amount of mtDNA depletes cGAS-STING-TBK1 signaling, leading to suppressed levels of autophagy and mitophagy. These responses further impair clearance of Aβ and mitochondria, ultimately resulting in heart dysfunction. Melatonin supplementation protects heart function in AD by boosting ALDH2 activity through PKCε, thus restoring mitochondrial integrity, cGAS-STING-TBK1 signaling, and autophagy and mitophagy levelsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 70 references

Cited by

See all 135

Metadata

Authors
Wang, S., Wang, L., Qin, X., Turdi, S., Sun, D., Culver, B., Reiter, R. J., Wang, X., Zhou, H., & Ren, J.
Affiliations
  • Tongji University (CN)
  • Xijing Hospital (CN)
  • University of Wyoming (US)
  • The University of Texas at San Antonio Health Science Center (US)
Corresponding author
  • Wang, Xiaoming
  • Zhou, Hao
  • Ren, Jun
Venue
Signal Transduction and Targeted Therapy
Published
2020-07-24
Volume
5
Issue
1
Pages
119-119
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3045457883
Cited by
135
References
70
Citations by year
2026: 10 · 2025: 30 · 2024: 28 · 2023: 26 · 2022: 17 · 2021: 17 · 2020: 7
FWCI
10.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM103432)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords
Alzheimer's disease, melatonin, ALDH2, mitophagy, APP/PS1 mice, cardiac dysfunction, autophagy, cardiomyocyte apoptosis, myocardial fibrosis, amyloid-beta, luzindole, melatonin receptors
MeSH terms
Aldehyde Dehydrogenase, Mitochondrial, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Animals, Heart Defects, Congenital, Humans, Melatonin, Membrane Proteins, Mutation, Nucleotidyltransferases, Amyloid beta-Protein Precursor, Mice, Knockout, Adaptor Proteins, Signal Transducing, Mice, Presenilin-1, Mitophagy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ALDH2 contributes to melatonin-induced protection against APP/PS1 mutation-prompted cardiac anomalies through cGAS-STING-TBK1-mediated regulation of mitophagy. https://app.cochat.ai/papers/10.1038/s41392-020-0171-5
The paper
Wang, S., Wang, L., Qin, X., Turdi, S., Sun, D., Culver, B., Reiter, R. J., Wang, X., Zhou, H., & Ren, J. (2020). ALDH2 contributes to melatonin-induced protection against APP/PS1 mutation-prompted cardiac anomalies through cGAS-STING-TBK1-mediated regulation of mitophagy. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-0171-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.